Aristides Capital LLC Increases Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Aristides Capital LLC increased its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 241,587 shares of the company's stock after acquiring an additional 41,587 shares during the quarter. Eton Pharmaceuticals makes up about 0.7% of Aristides Capital LLC's investment portfolio, making the stock its 23rd largest position. Aristides Capital LLC owned approximately 0.93% of Eton Pharmaceuticals worth $3,218,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ETON. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth approximately $54,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at $90,000. Geode Capital Management LLC raised its position in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after acquiring an additional 32,365 shares in the last quarter. Westside Investment Management Inc. lifted its position in shares of Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock valued at $3,711,000 after buying an additional 33,275 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at about $373,000. 27.86% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. B. Riley reaffirmed a "buy" rating and issued a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Trading Up 2.2 %

ETON traded up $0.27 during midday trading on Friday, hitting $12.24. 114,990 shares of the company were exchanged, compared to its average volume of 168,885. The firm has a market capitalization of $328.12 million, a price-to-earnings ratio of -55.68 and a beta of 1.34. The company's 50 day simple moving average is $14.64 and its 200 day simple moving average is $12.38. Eton Pharmaceuticals, Inc. has a 1-year low of $3.03 and a 1-year high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million. On average, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.